ABCT Mentor

Adam Hanina is the CEO and founder of Dandelion, the world’s first Generative Neuromodulation™ platform to treat vision and brain disorders. Previously, Adam founded AiCure, an NIH-funded advanced data analytics / computer vision company selling to the top 30 life science companies. As CEO, he grew the team to 100 people and sales into 8 digits.

Adam has invented platform technologies ranging from AI-patient monitoring to fractal barcodes and holds 52 awarded patents where he is listed as the primary inventor. He has raised over $58M in capital in addition to $8.9M in funding from the National Institutes of Health and the Swiss Innovation Agency. Alongside scientific publications in the fields of artificial intelligence and patient monitoring, Adam has been invited to speak in the US and globally at CES, BIO, DIA, WHO, Wharton, FT, Cooper Union, MIT, etc. His contributions to the life sciences have been recognized by multiple awards, including the PharmaVOICE 100. He holds an MBA from the Wharton School of Business, an MPhil from Cambridge University, and a BA with Honors in Physics and Economics from Brown University.